JDRF T1D Fund
Venture capitalBoston · Seed–Late Stage · 7 people tracked
Investment thesis
The T1D Fund, established in 2016, invests in early-stage companies developing disease-modifying therapies and potential cures for type 1 diabetes, typically alongside venture capital and biopharma partners.
Team · 7 people
from the firm's websiteFrequently asked questions
- What stage does JDRF T1D Fund invest at?
- JDRF T1D Fund invests at the Seed, Series A, Late Stage stages.
- What sectors does JDRF T1D Fund focus on?
- JDRF T1D Fund focuses on Biotech, Medical Devices.
- Where is JDRF T1D Fund located?
- JDRF T1D Fund is headquartered in Boston, US.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
Khosla Ventures is a technology-focused investment firm that seeks companies leveraging disruptive technological advances to solve large-scale problems across multiple industries. The firm emphasizes proprietary technology, business model innovation, and early-stage, bold investments with unfair advantages.
A European investment firm established in 2016 by former Index Ventures life sciences professionals with over 20 years of experience in drug discovery and therapeutic development for unmet medical needs.